相关实验视频

Updated: Jan 10, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

针对尿路癌的生物标志物驱动疗法

Sara Coca Membribes¹, Bernadett Szabados², Thomas Powles³

¹Barts Cancer Institute, Queen Mary University of London, Barts Health NHS Trust Biomedical Research Centre, London, UK. sara.membribes@nhs.net.

Nature reviews. Clinical oncology

|November 27, 2025

概括

识别新的生物标志物对于推进尿路细胞癌治疗至关重要. 这篇评论讨论了有希望的候选人,如循环瘤DNA用于向治疗和免疫检查点抑制剂.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
免疫学免疫学免疫学

背景情况:

晚期泌尿腺癌 (aUC) 治疗正在使用分子向药物和免疫检查点抑制剂 (ICI) 发展.
对这些疗法的生物标志物鉴定面临挑战,PD-L1表达的预测价值不一致.
FGFR3突变是可操作的生物标志物,但需要进一步的预后和预测标志物.

研究的目的:

审查晚期泌尿腺癌生物标志物的当前发展情况.
讨论针对性疗法和ICI新兴生物标志物的潜在临床实用性.

主要方法:

关于尿癌中的生物标志物的最近研究的文献综述.
对既定和新兴生物标志物的分析,包括遗传突变,蛋白质表达和循环瘤DNA.

主要成果:

FGFR3突变是FGFR抑制剂的验证生物标志物.
瘤突变负担和HER2过度表达显示出作为预测生物标志物的前景.
循环瘤DNA (ctDNA) 正成为一种有价值的预后生物标志物和响应监测.

结论:

对新生物标志物的持续研究对于优化aUC的治疗策略至关重要.
循环瘤DNA为患者管理提供了最少的侵入性方法.
对于aUC的个性化治疗选择,可能需要采用多种生物标志物方法.

更多相关视频

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis

Published on: May 12, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...